ADCS prevention instrument project: Overview and initial results

被引:59
作者
Ferris, Steven H.
Aisen, Paul S.
Cummings, Jeffrey
Galasko, Douglas
Salmon, David P.
Schneider, Lon
Sano, Mary
Whitehouse, Peter J.
Edland, Steven
Thal, Leon J.
机构
[1] NYU, Sch Med, Alzheimers Dis Ctr, New York, NY 10016 USA
[2] Georgetown Univ, Washington, DC USA
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] Univ Calif San Diego, La Jolla, CA 92093 USA
[5] Univ So Calif, Los Angeles, CA USA
[6] CUNY Mt Sinai Sch Med, New York, NY 10029 USA
[7] Case Western Reserve Univ, Cleveland, OH 44106 USA
关键词
Alzheimer disease; primary prevention; assessment measures; cognitive performance; global change; activities of daily living; behavior; quality of life; pharmaco-economics; mail-in questionnaires; telephone assessment; clinical trials;
D O I
10.1097/01.wad.0000213870.40300.21
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
One objective of the Alzheimer's Disease Cooperative Study (ADCS) is to develop new or improved instruments and assessment methods for evaluating treatment efficacy in Alzheimer disease (AD) clinical trials. The ADCS Instrument Committee has previously helped to define the state of the art in assessment for AD and Mild Cognitive Impairment clinical trials. We are now entering an exciting era of primary prevention trials to evaluate promising treatments that may delay disease onset and there is a need to develop appropriate instruments for these trials. The ADCS instrument committee has undertaken a project to develop instruments for prevention studies that assess domains known to be important in AD. Prevention trials are long and require large numbers of subjects, making them costly and requiring a high burden of participation for subjects. The current study focused on developing instruments that can be completed at home and in the clinic. The instruments are being evaluated in a cohort of nondemented elderly participating in a 4-year longitudinal study that simulates the design of a primary prevention trial. This report describes the design, baseline characteristics, and some longitudinal outcomes of the study cohort through the completion of the first 2 years of follow-up. We also describe the assessment domains to be measured with our new experimental instruments. This study recruited 644 subjects, 75 years of age and older. Participation in a "book club" that provided free books of interest to elders was offered as a recruitment incentive. Approximately 23% had some mild cognitive symptoms consistent with a Clinical Dementia Rating of 0.5. All subjects received a standardized in-clinic evaluation at baseline, which is repeated annually for 4 years to identify cases suspected of developing dementia and to measure longitudinal change on established clinical assessments. Subjects completed a set of self-administered experimental instruments at home or in the clinic designed to assess cognitive function and behavior, global change, activities of daily living, quality of life, and resource use. An additional "mail-in cognitive function questionnaire" was obtained separately by mail, 1 month before the other assessments. To evaluate the feasibility, efficiency, and validity of the home-based instruments in comparison with acquiring the same information during a clinic visit, subjects were randomized to I of 2 conditions in which the baseline and annual follow-up assessments are completed either at home ("home group") or at the study site during their clinic visits ("clinic group"). This initial report describes the ongoing 4-year longitudinal study and provides baseline results, which confirm the feasibility of obtaining home-based clinical information via mail or telephone. Initial results for the experimental instruments and for the book club are reported in separate accompanying articles.
引用
收藏
页码:S109 / S123
页数:15
相关论文
共 45 条
[1]   Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].
Aisen, PS ;
Schafer, KA ;
Grundman, M ;
Pfeiffer, E ;
Sano, M ;
Davis, KL ;
Farlow, MR ;
Jin, S ;
Thomas, RG ;
Thal, LJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826
[2]   Quality of life in patients with Alzheimer's disease as reported by patient proxies. [J].
Albert, SM ;
DelCastilloCastaneda, C ;
Sano, M ;
Jacobs, DM ;
Marder, K ;
Bell, K ;
Bylsma, F ;
Lafleche, G ;
Brandt, J ;
Albert, M ;
Stern, Y .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1996, 44 (11) :1342-1347
[3]  
[Anonymous], CLIN GERONTOLOGY GUI
[4]  
BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637
[6]   A COEFFICIENT OF AGREEMENT FOR NOMINAL SCALES [J].
COHEN, J .
EDUCATIONAL AND PSYCHOLOGICAL MEASUREMENT, 1960, 20 (01) :37-46
[7]   ADCS Prevention Instrument Project: Behavioral measures in primary prevention trials [J].
Cummings, Jeffrey L. ;
Raman, Rema ;
Ernstrom, Karin ;
Salmon, David ;
Ferris, Steven H. .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2006, 20 (04) :S147-S151
[8]   THE NEUROPSYCHIATRIC INVENTORY - COMPREHENSIVE ASSESSMENT OF PSYCHOPATHOLOGY IN DEMENTIA [J].
CUMMINGS, JL ;
MEGA, M ;
GRAY, K ;
ROSENBERGTHOMPSON, S ;
CARUSI, DA ;
GORNBEIN, J .
NEUROLOGY, 1994, 44 (12) :2308-2314
[9]   SIZE AND POWER OF 2-SAMPLE TESTS OF REPEATED-MEASURES DATA [J].
DAWSON, JD ;
LAGAKOS, SW .
BIOMETRICS, 1993, 49 (04) :1022-1032
[10]   THE SATISFACTION WITH LIFE SCALE [J].
DIENER, E ;
EMMONS, RA ;
LARSEN, RJ ;
GRIFFIN, S .
JOURNAL OF PERSONALITY ASSESSMENT, 1985, 49 (01) :71-75